An international research agenda for clozapine-resistant schizophrenia

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

An international research agenda for clozapine-resistant schizophrenia. / Luykx, Jurjen J; Gonzalez-Diaz, Jairo M; Guu, Ta-Wei; van der Horst, Marte Z; van Dellen, Edwin; Boks, Marco P; Guloksuz, Sinan; DeLisi, Lynn E; Sommer, Iris E; Cummins, Russel; Shiers, David; Lee, Jimmy; Every-Palmer, Susanna; Mhalla, Ahmed; Chadly, Zohra; Chan, Sherry K W; Cotes, Robert O; Takahashi, Shun; Benros, Michael E; Wagner, Elias; Correll, Christoph U; Hasan, Alkomiet; Siskind, Dan; Endres, Dominique; MacCabe, James; Tiihonen, Jari.

I: The lancet. Psychiatry, Bind 10, Nr. 8, 2023, s. 644-652.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Luykx, JJ, Gonzalez-Diaz, JM, Guu, T-W, van der Horst, MZ, van Dellen, E, Boks, MP, Guloksuz, S, DeLisi, LE, Sommer, IE, Cummins, R, Shiers, D, Lee, J, Every-Palmer, S, Mhalla, A, Chadly, Z, Chan, SKW, Cotes, RO, Takahashi, S, Benros, ME, Wagner, E, Correll, CU, Hasan, A, Siskind, D, Endres, D, MacCabe, J & Tiihonen, J 2023, 'An international research agenda for clozapine-resistant schizophrenia', The lancet. Psychiatry, bind 10, nr. 8, s. 644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

APA

Luykx, J. J., Gonzalez-Diaz, J. M., Guu, T-W., van der Horst, M. Z., van Dellen, E., Boks, M. P., Guloksuz, S., DeLisi, L. E., Sommer, I. E., Cummins, R., Shiers, D., Lee, J., Every-Palmer, S., Mhalla, A., Chadly, Z., Chan, S. K. W., Cotes, R. O., Takahashi, S., Benros, M. E., ... Tiihonen, J. (2023). An international research agenda for clozapine-resistant schizophrenia. The lancet. Psychiatry, 10(8), 644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

Vancouver

Luykx JJ, Gonzalez-Diaz JM, Guu T-W, van der Horst MZ, van Dellen E, Boks MP o.a. An international research agenda for clozapine-resistant schizophrenia. The lancet. Psychiatry. 2023;10(8):644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

Author

Luykx, Jurjen J ; Gonzalez-Diaz, Jairo M ; Guu, Ta-Wei ; van der Horst, Marte Z ; van Dellen, Edwin ; Boks, Marco P ; Guloksuz, Sinan ; DeLisi, Lynn E ; Sommer, Iris E ; Cummins, Russel ; Shiers, David ; Lee, Jimmy ; Every-Palmer, Susanna ; Mhalla, Ahmed ; Chadly, Zohra ; Chan, Sherry K W ; Cotes, Robert O ; Takahashi, Shun ; Benros, Michael E ; Wagner, Elias ; Correll, Christoph U ; Hasan, Alkomiet ; Siskind, Dan ; Endres, Dominique ; MacCabe, James ; Tiihonen, Jari. / An international research agenda for clozapine-resistant schizophrenia. I: The lancet. Psychiatry. 2023 ; Bind 10, Nr. 8. s. 644-652.

Bibtex

@article{404d560af8694aeb85032a01722bafe3,

title = "An international research agenda for clozapine-resistant schizophrenia",

abstract = "Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.",

author = "Luykx, {Jurjen J} and Gonzalez-Diaz, {Jairo M} and Ta-Wei Guu and {van der Horst}, {Marte Z} and {van Dellen}, Edwin and Boks, {Marco P} and Sinan Guloksuz and DeLisi, {Lynn E} and Sommer, {Iris E} and Russel Cummins and David Shiers and Jimmy Lee and Susanna Every-Palmer and Ahmed Mhalla and Zohra Chadly and Chan, {Sherry K W} and Cotes, {Robert O} and Shun Takahashi and Benros, {Michael E} and Elias Wagner and Correll, {Christoph U} and Alkomiet Hasan and Dan Siskind and Dominique Endres and James MacCabe and Jari Tiihonen",

year = "2023",

doi = "10.1016/S2215-0366(23)00109-8",

language = "English",

volume = "10",

pages = "644--652",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "TheLancet Publishing Group",

number = "8",

}

RIS

TY - JOUR

T1 - An international research agenda for clozapine-resistant schizophrenia

AU - Luykx, Jurjen J

AU - Gonzalez-Diaz, Jairo M

AU - Guu, Ta-Wei

AU - van der Horst, Marte Z

AU - van Dellen, Edwin

AU - Boks, Marco P

AU - Guloksuz, Sinan

AU - DeLisi, Lynn E

AU - Sommer, Iris E

AU - Cummins, Russel

AU - Shiers, David

AU - Lee, Jimmy

AU - Every-Palmer, Susanna

AU - Mhalla, Ahmed

AU - Chadly, Zohra

AU - Chan, Sherry K W

AU - Cotes, Robert O

AU - Takahashi, Shun

AU - Benros, Michael E

AU - Wagner, Elias

AU - Correll, Christoph U

AU - Hasan, Alkomiet

AU - Siskind, Dan

AU - Endres, Dominique

AU - MacCabe, James

AU - Tiihonen, Jari

PY - 2023

Y1 - 2023

N2 - Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

AB - Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

U2 - 10.1016/S2215-0366(23)00109-8

DO - 10.1016/S2215-0366(23)00109-8

M3 - Review

C2 - 37329895

VL - 10

SP - 644

EP - 652

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

SN - 2215-0366

IS - 8

ER -

ID: 358164008